Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

NiSource Q2 EPS $0.13, Inline

NiSource (NYSE:NI) reported quarterly earnings of $0.13 per share which met the analyst consensus estimate. This is unchanged from the same period last year.

byBenzinga Newsdesk

August 4, 2021

1 minute read

NiSource (NYSE:NI) reported quarterly earnings of $0.13 per share which met the analyst consensus estimate. This is unchanged from the same period last year.

Truist Securities Maintains Buy on Essex Property Trust, Lowers Price Target to $247

By Benzinga Newsdesk

Today, 8:56 PM

Truist Securities analyst Michael Lewis maintains Essex Property Trust (NYSE:ESS) with a Buy and lowers the price target from $324 to $247.

ESS

Wolfe Research Upgrades PPL to Outperform, Raises Price Target to $30

By Benzinga Newsdesk

Today, 8:56 PM

Wolfe Research analyst Steve Fleishman upgrades PPL (NYSE:PPL) from Peer Perform to Outperform and raises the price target from $28 to $30.

PPL

Canada Approves Edesa Biotech’s COVID-19 Trial For EB05 Antibody As Rescue Therapy

By Vandana Singh

Today, 8:56 PM

Health Canada has approved to test Edesa Biotech Inc’s (NASDAQ:EDSA) monoclonal antibody candidate, designated EB05, as COVID-19 rescue therapy for critically…

EDSA

Evercore ISI Group Maintains Outperform on Monster Beverage, Raises Price Target to $115

By Benzinga Newsdesk

Today, 8:56 PM

Evercore ISI Group analyst Robert Ottenstein maintains Monster Beverage (NASDAQ:MNST) with a Outperform and raises the price target from $105 to $115.

MNST

NiSource Q2 EPS $0.13, Inline

Related Posts

Truist Securities Maintains Buy on Essex Property Trust, Lowers Price Target to $247

Wolfe Research Upgrades PPL to Outperform, Raises Price Target to $30

Canada Approves Edesa Biotech’s COVID-19 Trial For EB05 Antibody As Rescue Therapy

Evercore ISI Group Maintains Outperform on Monster Beverage, Raises Price Target to $115